Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up

Kusamura, Shigeki; Képénékian, Vahan; Villeneuve, Laurent; Lurvink, Robin J.; Govaerts, Kim; Hingh, I.H.J.T. de; Moran, Brendan; Speeten, Kurt Van der; Deraco, Marcello; Gléhen, Olivier; Barrios-Sánchez, Pedro; Baumgartner, Joel M.; Ben‐Yaacov, Almog; Bertulli, Rossella; Cashin, Peter; Cecil, Tom; Dayal, Sanjeev; Simone, Michele De; Foster, Jason M.; Goèré, Diane; Lehmann, Kuno; Li, Yan; Loggie, Brian W.; Mohamed, Faheez; Morris, David L.; Nissan, Aviram; Piso, Pompiliu; Pocard, Marc; Rau, Beate; Reymond, Marc A.; Sidéris, Lucas; Spiliotis, John; Sugarbaker, Paul H.; Verwaal, Victor J.; Wilson, Malcom S.; Yonemura, Yutaka; Yu, Yang

doi:10.1016/j.ejso.2020.02.011

Cited by 76 publications

(128 citation statements)

References 112 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Other mineral fibers likely play a causative role, with the silicate fiber erionite also being a potent inducer of MPM. In addition, other factors described include therapeutic radiation, papovirus, simian virus, chronic inflammation, and inherited susceptibility [1][2][3].…”

Section: Discussionmentioning

confidence: 99%

“…However, definitive diagnosis is by biopsy, which can be guided by radiology (CT) or surgery. MPM includes three histologic subtypes: epithelioid (as seen in our case), sarcomatous, and biphasic [1][2][3][4][5][6][7]. There is no uniformly accepted classification system for MPM.…”

Section: Discussionmentioning

confidence: 99%

“…Other pathologies such as peritoneal carcinomatosis secondary to gastrointestinal or ovarian neoplasm, as well as peritoneal tuberculosis, must be dismissed [1][2][3].…”

Section: Discussionmentioning

confidence: 99%

“…The selection of the best therapeutic management should be done by a multidisciplinary team specialized in this type of neoplasm, with the current therapeutic options being both cytoreductive surgery with intraperitoneal hyperthermic chemotherapy or systemic chemotherapy [1][2][3][4]9]. The patients who benefit from this first, more aggressive therapy are those with good performance status (defined as Eastern Cooperative Oncology Group score 0 or 1), disease distribution favorable for complete or near-complete cytoreductive surgery (extension and depth of the tumor disease does not affect beyond the mesothelial surface), epithelioid histology, female sex (female patients survive longer than male patients), age <60 years, and absence of pretreatment thrombocytosis [1][2][3][4][9][10][11]. However, for those patients who do not meet these characteristics or whose condition is not operable, systemic chemotherapy (cisplatin and pemetrexed) must be considered, although the disease is usually refractory to the usual regimens [1][2][3][4]9].…”

Section: Discussionmentioning

confidence: 99%

“…Malignant peritoneal mesothelioma (MPM) is a rare neoplasm that accounts for 10%-15% of all mesothelioma cases and it is associated up to 50% of the time with asbestosis. It usually presents without differences in terms of sex, with a mean age of 64 years and related to the intra-abdominal locoregional effect, insidiously in the form of abdominal pain or distension [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

“Omental Cake” in a Patient With Asbestosis Leading to the Diagnosis of Malignant Peritoneal Mesothelioma

Martínez

Guerrero

Gonzaga

2021

Cureus

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Other pathologies such as peritoneal carcinomatosis secondary to gastrointestinal or ovarian neoplasm, as well as peritoneal tuberculosis, must be dismissed [1][2][3].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

“Omental Cake” in a Patient With Asbestosis Leading to the Diagnosis of Malignant Peritoneal Mesothelioma

Martínez

Guerrero

Gonzaga

2021

Cureus

View full text Add to dashboard Cite

show abstract

Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes

Deban

Taqi

Knapp

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

IntroductionPeritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is the standard‐of‐care for patients with isolated PM. Due to a paucity of prospective data there are several different HIPEC protocols. The aims of this study are to describe the CRS and HIPEC protocols for PM and patient outcomes across Canada.MethodsA multicenter retrospective study was performed on patients diagnosed and treated for PM with CRS and HIPEC in four major peritoneal disease centers in Canada between 2000 and 2021. Data on patient characteristics, treatment patterns, postoperative morbidity, recurrence, and survival were collected.ResultsA total of 72 patients were identified. Mean age was 52 years (17–75) and 37.5% were male. Epithelioid (70.1%) and multicystic (13%) mesothelioma were the most common subtypes. Twenty‐one patients (30%) were treated with neoadjuvant chemotherapy. CRS and HIPEC was performed in 64 patients (91.4%). Of these, the mean PCI was 22 (2–39) and cisplatin+doxorubicin was the most common HIPEC regimen (n = 33, 51.6%). A semi‐closed coliseum technique was used in 68.8% of HIPECs and the mean duration of surgery was 486 min (90–1052). Clavien‐Dindo III or IV complications occurred in 12 patients (16.9%). With a median follow‐up of 24 months (0.2–104.4), we found a 5‐year overall survival of 61% and a 5‐year recurrence‐free survival of 35%.ConclusionCRS and HIPEC is a safe and effective treatment modality for well‐selected patients with PM, with some achieving prolonged survival.

show abstract

Review of 2022 PSOGI/RENAPE Consensus on HIPEC

Kusamura,

Bhatt,

van Der Speeten

et al. 2024

Journal of Surgical Oncology

View full text Add to dashboard Cite

The 2022 PSOGI (Peritoneal Surface Oncology Group International) and RENAPE (French Network for Rare Peritoneal Malignancies) consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) was a comprehensive effort aimed at standardizing treatment protocols for various peritoneal malignancies. This initiative is critical due to the wide range of technical variations in HIPEC procedures and the resulting need for standardization to ensure consistent and effective patient care and meaningful audit of multicenter data.

show abstract

Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up

Cited by 76 publications

References 112 publications

“Omental Cake” in a Patient With Asbestosis Leading to the Diagnosis of Malignant Peritoneal Mesothelioma

“Omental Cake” in a Patient With Asbestosis Leading to the Diagnosis of Malignant Peritoneal Mesothelioma

Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes

Review of 2022 PSOGI/RENAPE Consensus on HIPEC

Contact Info

Product

Resources

About